The study will assess the efficacy and safety of proxalutamide in hospitalised Covid-19 patients. Credit: DoroT Schenk from Pixabay.

Kintor Pharmaceutical has dosed the first subject in the US for the Phase III clinical trial of its oral drug, proxalutamide, to treat hospitalised Covid-19 patients.

Proxalutamide is a selective high-affinity silent antagonist of the androgen receptor, which is currently being developed to treat Covid-19, breast cancer and prostate cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is claimed to be the only small-molecule oral drug that has entered the Phase III multi-regional clinical trial (MRCT).

The latest move follows the Brazilian Health Regulatory Agency’s (ANVISA) approval last month to conduct the Phase III clinical trial of proxalutamide.

The randomised, double-blind, placebo-controlled, multi-regional pivotal trial has also been approved by the US Food and Drug Administration (FDA).

It is the third ANVISA-approved clinal trial, which is sponsored by the company to treat Covid-19 patients with proxalutamide.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The study will assess the efficacy and safety of proxalutamide in hospitalised patients. Time to sustained recovery evaluated by day 30 will be the primary endpoint, while the 30-day mortality will be the secondary endpoint.

Kintor Pharmaceutical chairman and CEO Youzhi Tong said: “More than 100 sites in 14 countries participate in this MRCT clinical trial, which has been greenlighted/approved by the US FDA, China CDE, Philippines FDA and Brazilian ANVISA, and we continue to seek for approvals by regulatory agencies in European and Asian countries.

“This pivotal study has taken reference to the positive data on efficiency and safety profile of proxalutamide’s treating hospitalised Covid 19 patients in the IIT study conducted in Brazil earlier this year.”

The company is currently conducting two registered Phase III MRCTs of proxalutamide to treat Covid-19 outpatients.

One Phase III MRCT for Covid-19 inpatients is being conducted in the US, South America, including Brazil, the EU, and Asia.

In July this year, Kintor has signed a licensing agreement with Shanghai Fosun Pharmaceutical Development to market proxalutamide in India and 28 African countries.